These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10597772)

  • 61. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost?
    Sibiude J; Warszawski J; Tubiana R; Dollfus C; Faye A; Rouzioux C; Teglas JP; Ekoukou D; Blanche S; Mandelbrot L
    Clin Infect Dis; 2012 May; 54(9):1348-60. PubMed ID: 22460969
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Problems in the management of HIV infection in clinical practice. Patients still on dual therapy 8 years after the introduction of HAART].
    Manfredi R
    Recenti Prog Med; 2003 Nov; 94(11):506-7. PubMed ID: 14679919
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P; Cozzi-Lepri A; Phillips A; Puoti M; Antonucci G; Manconi PE; Tositti G; Colangeli V; Lichtner M; Monforte Ad;
    AIDS; 2007 Mar; 21(5):599-606. PubMed ID: 17314522
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients.
    Hernandez LV; Gilson I; Jacobson J; Affi A; Puetz TR; Dindzans VJ
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1627-32. PubMed ID: 11564003
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 71. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008.
    Bruyand M; Dabis F; Vandenhende MA; Lazaro E; Neau D; Leleux O; Geffard S; Morlat P; Chêne G; Bonnet F
    J Hepatol; 2011 Nov; 55(5):1058-62. PubMed ID: 21354449
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART.
    Jevtović Dj; Ranin J; Salemović D; Pesić I; Dragović G; Zerjav S; Djurković-Djaković O
    Biomed Pharmacother; 2008 Jan; 62(1):21-5. PubMed ID: 17223307
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.
    Iniesta-Navalón C; Franco-Miguel JJ; Gascón-Cánovas JJ; Rentero-Redondo L
    HIV Med; 2015 May; 16(5):273-9. PubMed ID: 25523089
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors.
    Galli M; Ridolfo AL; Adorni F; Gervasoni C; Ravasio L; Corsico L; Gianelli E; Piazza M; Vaccarezza M; d'Arminio Monforte A; Moroni M
    J Acquir Immune Defic Syndr; 2002 Jan; 29(1):21-31. PubMed ID: 11782586
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease.
    Merchante N; Girón-González JA; González-Serrano M; Torre-Cisneros J; García-García JA; Arizcorreta A; Ruiz-Morales J; Cano-Lliteras P; Lozano F; Martínez-Sierra C; Macías J; Pineda JA;
    AIDS; 2006 Jan; 20(1):49-57. PubMed ID: 16327319
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)].
    Vennarecci G; Ettorre GM; Antonini M; Maritti M; Moricca P; D'Offizzi G; Narciso P; Lonardo MT; Boschetto A; Del Nonno F; Perracchio L; Palmieri GP; Visco G; Santoro E
    Tumori; 2003; 89(4 Suppl):159-61. PubMed ID: 12903579
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy.
    Yacisin K; Maida I; Ríos MJ; Soriano V; Núñez M
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):935-40. PubMed ID: 18593347
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
    French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
    Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Factors associated with the occurrence of AIDS-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: Aquitaine Cohort, France.
    Bonnet F; Balestre E; Thiébaut R; Morlat P; Pellegrin JL; Neau D; Dabis F;
    Clin Infect Dis; 2006 Feb; 42(3):411-7. PubMed ID: 16392091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.